Bionime Corporation
Clinical trials sponsored by Bionime Corporation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- An open-label, multicenter, randomized, parallel-group trial to assess glycemic control with the RIGHTEST iFree 2 continuous glucose monitoring system in adults with diabetes mellitus Results expected Dec 2026 (estimated)
- Evaluation of the effectiveness and safety of the RIGHTEST™ iFree 2 continuous glucose monitoring system in pregnant women with diabetes mellitus Results expected Mar 2027 (estimated)
-
Evaluation of the effectiveness and safety of the RIGHTEST™ iFree 2 continuous glucose monitoring system in pregnant women with diabetes mellitus
Recruiting nowThis study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes. The system uses a small sensor placed under the skin to measure glucose levels in …
Sponsor: Bionime Corporation
Last updated Oct 24, 2026 00:00 UTC
-
An open-label, multicenter, randomized, parallel-group trial to assess glycemic control with the RIGHTEST iFree 2 continuous glucose monitoring system in adults with diabetes mellitus
Recruiting nowThe goal of this clinical trial is to find out whether using a real-time continuous glucose monitoring (CGM) system can improve daily blood sugar control compared with usual self-monitoring of blood glucose (SMBG; finger-stick testing) in people with diabetes who are treated with…
Sponsor: Bionime Corporation
Last updated Oct 24, 2026 00:00 UTC